Zoetis Ltd announced on February 23 that there will be a supply issue with Equip® Artervac.
Equip Artervac is a part of the Zoetis Equip range of vaccines. It is indicated for the active immunization for horses against equine viral arteritis (EVA) to reduce the clinical signs and shedding of the virus in nasal secretions following infection.
The current inventory of Equip Artervac has an expiry date of March 29, 2023. Zoetis is not expecting a new batch to be available until the end of September 2023.
Zoetis has been working closely with the relevant organizations to implement a plan to mitigate the impact to breeders.
The Thoroughbred Breeders Association has published advice for a blood sampling scheme. Please visit:
Please note this requires action two weeks after the most recent EVA vaccination, so please ensure you familiarize yourself with these guidelines in plenty of time.
We sincerely apologize for any inconvenience that this supply issue might cause. Zoetis confirms its commitment to providing further information as soon as possible.
The VMD and DEFRA have been notified about the situation.
For further information contact your Zoetis Account Manager or the Zoetis Technical Team on [email protected] or 0345 300 8034.
As the world’s leading animal health company, we are driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years of innovating ways to predict, prevent, detect, and treat animal illness, we continue to stand by those raising and caring for animals worldwide, from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in more than 100 countries. A Fortune 500 company, Zoetis generated revenue of $7.8 billion in 2021 with approximately 12,100 employees. For more information, visit www.zoetis.com.